Form 4: 10X Fund Reduces Galectin Therapeutics Stake

10X Fund, L.P., a 10% owner and director of Galectin Therapeutics Inc., reported the sale of 50,000 shares of common stock for approximately $246,800.

Summary

• 10X Fund, L.P., a reporting person identified as a Director and 10% Owner of Galectin Therapeutics Inc. (GALT), sold a total of 50,000 shares of common stock.
• The sales occurred on October 22, 2025, and were executed in two separate transactions.
• The first transaction involved the sale of 20,000 shares at a price of $4.93 per share.
• The second transaction involved the sale of 30,000 shares at a price of $4.94 per share.
• Following these transactions, 10X Fund, L.P. directly beneficially owns 5,872,207 shares of Galectin Therapeutics Inc. common stock.
• The transactions were not indicated as being made pursuant to a Rule 10b5-1 pre-planned trading arrangement.
• 10X Capital Management, LLC, as the general partner of 10X Fund, L.P., and James C. Czirr, as the manager of 10X Capital Management, LLC, may be deemed to have indirect beneficial ownership but disclaim ownership except to the extent of their pecuniary interest.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to a significant insider sale by a 10% owner and director, especially given that it was not part of a pre-planned trading arrangement, which could signal a lack of confidence or a belief that the stock is fully valued.

Negatives

• A significant insider (10% owner and director) sold 50,000 shares of common stock.
• The sale was not indicated as being part of a Rule 10b5-1 pre-planned trading arrangement, suggesting it may have been a discretionary sale.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• 10X Fund, L.P., a 10% owner and director of Galectin Therapeutics Inc., engaged in the sale of company common stock.

Stakeholder Impact

• Shareholders may perceive the insider selling as a negative indicator, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Recommendation

While the sale by a 10% owner and director is a negative signal, it represents a partial reduction rather than a full divestment. Investors should hold existing positions but exercise caution, closely monitoring future insider activity and company developments. The discretionary nature of the sale (not under a 10b5-1 plan) warrants careful consideration of potential underlying reasons.

Keywords

GALT, Galectin Therapeutics, 10X Fund, Insider Sale, Form 4, Common Stock, Director, 10% Owner, Equity Transaction